From 2011 to 2014, the BESIII experiment collected about 5 fb^-1 data at center-of-mass energies around 4 GeV for the studies of the charmonium-like and higher excited charmonium states. By analyzing the di-muon proce...From 2011 to 2014, the BESIII experiment collected about 5 fb^-1 data at center-of-mass energies around 4 GeV for the studies of the charmonium-like and higher excited charmonium states. By analyzing the di-muon process e＋e- →yma/Fsμ^＋μ^-, the center-of-mass energies of the data samples are measured with a precision of 0.8 MeV. The center-of-mass energy is found to be stable for most of the time during data taking.展开更多
Objective： To evaluate the efficacy and safety of Flos Abelmoschus manihot （Malvaceae） on type 2 diabetic nephropathy （DN）. Methods： The Cochrane Library, PubMed/MEDLINE, Excerpta Medical Database, Chinese elect...Objective： To evaluate the efficacy and safety of Flos Abelmoschus manihot （Malvaceae） on type 2 diabetic nephropathy （DN）. Methods： The Cochrane Library, PubMed/MEDLINE, Excerpta Medical Database, Chinese electronic literature databases, and the references of relevant articles were searched in March 2012 for randomized controlled trials （RCTs） that reported the effects of Flos A. manihot on type 2 DN patients with overt but subnephrotic-range proteinuria （500-3,500 mg/24 h）. The quality of trials was evaluated using the Cochrane-recommended method. The results were summarized as risk ratios （RRs） for dichotomous outcomes or mean differences （MDs） for continuous outcomes. Results： Seven trials （531 patients） were included. F/os A. manihot significantly decreased proteinuria [MD -317.32 mg/24 h, 95% confidence interval （CI） [-470.48, -164.17], P〈0.01]. After excluding a trial that only included patients with well-preserved renal function, F/os A. manihot was associated with a significant decrease in serum creatinine （MD -11.99 i~ mol/L, 95% CI [-16.95, -7.04], P〈0.01）. Serious adverse events were not observed. The most common adverse event was mild to moderate gastrointestinal discomfort; however, patients receiving this herb did not have an increased risk for tolerated gastrointestinal discomfort （RR 1.48, 95% CI [0.39, 5.68], P=0.57）. Conclusions： F/os A. manihot may be considered as an important adjunctive therapy with the first-line and indispensable therapeutic strategies for type 2 DN. High-quality RCTs are urgently needed to confirm the effect of Flos A. manihot on definite endpoints such as end-stage renal disease.展开更多
基金Supported by National Key Basic Research Program of China(2015CB856700)National Natural Science Foundation of China(11125525,11235011.11322544,11335008,11425524,Y61137005C)+7 种基金Chinese Academy of Sciences(CAS)Large-Scale Scientific Facility Program,CAS Center for Excellence in Particle Physics(CCEPP),Collaborative Innovation Center for Particles and Interactions(CICPI),Joint Large-Scale Scientific Facility Funds of NSFC and CAS(11179007,U1232201,U1332201),CAS(KJCX2-YW-N29,KJCX2-YWN45),100 Talents Program of CASNational 1000 Talents Program of China,INPACShanghai Key Laboratory for Particle Physics and Cosmology,German Research Foundation DFG(Collaborative Research Center CRC-1044)Istituto Nazionale di Fisica Nucleare,Italy,Ministry of Development of Turkey(DPT2006K-120470)Russian Foundation for Basic Research(14-07-91152)Swedish Research Council,U.S.Department of Energy(DE-FG02-04ER41291,DE-FG02-05ER41374,DE-FG02-94ER40823,DESC0010118)U.S.National Science Foundation,University of Groningen(RuG)and Helniholtzzentrum fuer Schwerionenforschung GmbH(GSI),DarmstadtWCU Program of National Research Foundation of Korea(R32-2008-000-10155-0)
文摘From 2011 to 2014, the BESIII experiment collected about 5 fb^-1 data at center-of-mass energies around 4 GeV for the studies of the charmonium-like and higher excited charmonium states. By analyzing the di-muon process e＋e- →yma/Fsμ^＋μ^-, the center-of-mass energies of the data samples are measured with a precision of 0.8 MeV. The center-of-mass energy is found to be stable for most of the time during data taking.
基金Supported by National Major New Drug Creation Plan of China(No.2013ZX09104003)Key Science and Technology Planning of Science and Technology Commission Foundation of Beijing,China(No.D131100004713000)
文摘Objective： To evaluate the efficacy and safety of Flos Abelmoschus manihot （Malvaceae） on type 2 diabetic nephropathy （DN）. Methods： The Cochrane Library, PubMed/MEDLINE, Excerpta Medical Database, Chinese electronic literature databases, and the references of relevant articles were searched in March 2012 for randomized controlled trials （RCTs） that reported the effects of Flos A. manihot on type 2 DN patients with overt but subnephrotic-range proteinuria （500-3,500 mg/24 h）. The quality of trials was evaluated using the Cochrane-recommended method. The results were summarized as risk ratios （RRs） for dichotomous outcomes or mean differences （MDs） for continuous outcomes. Results： Seven trials （531 patients） were included. F/os A. manihot significantly decreased proteinuria [MD -317.32 mg/24 h, 95% confidence interval （CI） [-470.48, -164.17], P〈0.01]. After excluding a trial that only included patients with well-preserved renal function, F/os A. manihot was associated with a significant decrease in serum creatinine （MD -11.99 i~ mol/L, 95% CI [-16.95, -7.04], P〈0.01）. Serious adverse events were not observed. The most common adverse event was mild to moderate gastrointestinal discomfort; however, patients receiving this herb did not have an increased risk for tolerated gastrointestinal discomfort （RR 1.48, 95% CI [0.39, 5.68], P=0.57）. Conclusions： F/os A. manihot may be considered as an important adjunctive therapy with the first-line and indispensable therapeutic strategies for type 2 DN. High-quality RCTs are urgently needed to confirm the effect of Flos A. manihot on definite endpoints such as end-stage renal disease.
